Noncanonical TGF-β pathways, mTORC1 and Abl, in renal interstitial fibrogenesis

American Journal of Physiology - Renal Physiology

Volumn 298, Issue 1, 2010, Pages

  Wang, Shinong ^a   Wilkes, Mark C ^b   Leof, Edward B ^b   Hirschberg, Raimund ^a  

^a UCLA MEDICAL CENTER   (United States)

^b MAYO CLINIC CANCER CENTER   (United States)

Author keywords

Imatinib; mTOR; Rapamycin

Indexed keywords

ABELSON KINASE; FIBRONECTIN; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN C1; P21 ACTIVATED KINASE 2; PROTEIN KINASE B; RAPAMYCIN; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUBERIN; UNCLASSIFIED DRUG; MADH2 PROTEIN, RAT; MADH3 PROTEIN, RAT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; TORC1 PROTEIN, RAT; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FIBROGENESIS; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KIDNEY FIBROSIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; ANIMAL; DISEASE MODEL; DOSE RESPONSE; DRUG ANTAGONISM; FIBROBLAST; FIBROSIS; KIDNEY; KIDNEY DISEASE; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; URETER OBSTRUCTION;

ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; FIBROSIS; KIDNEY; KIDNEY DISEASES; MALE; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SIROLIMUS; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA; URETERAL OBSTRUCTION;

EID: 74049137551     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00320.2009     Document Type: Article

References (23)

1. Bohle A, Strutz F, Muller GA. On the pathogenesis of chronic renal failure in primary glomerulopathies: a view from the interstitium. Exp Nephrol 2: 205-210, 1994.
2. Bohle A, Wehrmann M, Bogenschutz O, Batz C, Muller CA, Muller GA. The pathogenesis of chronic renal failure in diabetic nephropathy. Investigation of 488 cases of diabetic glomerulosclerosis. Pathol Res Pract 187: 251-259, 1991.
3. Bohle A, Wehrmann M, Mackensen-Haen S, Gise H, Mickeler E, Xiao TC, Muller C, Muller GA. Pathogenesis of chronic renal failure in primary glomerulopathies. Nephrol Dial Transplant 9, Suppl 3: 4-12, 1994.
4. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, Leof EB. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 114: 1308-1316, 2004.
5. Docherty NG, O'Sullivan OE, Healy DA, Fitzpatrick JM, Watson RW. Evidence that inhibition of tubular cell apoptosis protects against renal damage and development of fibrosis following ureteric obstruction. Am J Physiol Renal Physiol 290: F4-F13, 2006.
6. Fukuda K, Yoshitomi K, Yanagida T, Tokumoto M, Hirakata H. Quantification of TGF-β1 mRNA along rat nephron in obstructive nephropathy. Am J Physiol Renal Physiol 281: F513-F521, 2001.
7. Huang J, Dibble CC, Matsuzaki M, Manning BD. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol 28: 4104-4115, 2008.
8. Inoki K, Li Y, Xu T, Guan KL. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 17: 1829-1834, 2003.
9. Kaneto H, Ohtani H, Fukuzaki A, Ishidoya S, Takeda A, Ogata Y, Nagura H, Orikasa S. Increased expression of TGF-beta1 but not of its receptors contributes to human obstructive nephropathy. Kidney Int 56: 2137-2146, 1999.
10. Klahr S, Morrissey J. Obstructive nephropathy and renal fibrosis. Am J Physiol Renal Physiol 283: F861-F875, 2002.
11. Massague J, Seoane J, Wotton D. Smad transcription factors. Genes Dev 19: 2783-2810, 2005.
12. Prabhu S, Saadat D, Zhang M, Halbur L, Fruehauf JP, Ong ST. A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation. Oncogene 26: 1188-1200, 2007.
13. Rahimi RA, Andrianifahanana M, Wilkes MC, Edens M, Kottom TJ, Blenis J, Leof EB. Distinct roles for mammalian target of rapamycin complexes in the fibroblast response to transforming growth factor-beta. Cancer Res 69: 84-93, 2009.
14. Roberts AB, Russo A, Felici A, Flanders KC. Smad3: a key player in pathogenetic mechanisms dependent on TGF-beta. Ann NY Acad Sci 995: 1-10, 2003.
15. Roberts AB, Tian F, Byfield SD, Stuelten C, Ooshima A, Saika S, Flanders KC. Smad3 is key to TGF-beta-mediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasis. Cytokine Growth Factor Rev 17: 19-27, 2006.
16. Taft JL, Nolan CJ, Yeung SP, Hewitson TD, Martin FI. Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria. Diabetes 43: 1046-1051, 1994.
17. Wang S, Wilkes MC, Leof EB, Hirschberg R. Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. FASEB J 19: 1-11, 2005.
18. Wilkes MC, Leof EB. Transforming growth factor beta activation of c-Abl is independent of receptor internalization and regulated by phosphatidylinositol 3-kinase and PAK2 in mesenchymal cultures. J Biol Chem 281: 27846-27854, 2006.
19. Wilkes MC, Mitchell H, Penheiter SG, Dore JJ, Suzuki K, Edens M, Sharma DK, Pagano RE, Leof EB. Transforming growth factor-beta activation of phosphatidylinositol 3-kinase is independent of Smad2 and Smad3 and regulates fibroblast responses via p21-activated kinase-2. Cancer Res 65: 10431-10440, 2005.
20. Wilkes MC, Murphy SJ, Garamszegi N, Leof EB. Cell-type-specific activation of PAK2 by transforming growth factor beta independent of Smad2 and Smad3. Mol Cell Biol 23: 8878-8889, 2003.
21. Wu MJ, Wen MC, Chiu YT, Chiou YY, Shu KH, Tang MJ. Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis. Kidney Int 69: 2029-2036, 2006.
22. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 124: 471-484, 2006.
23. Yamamoto T, Noble NA, Miller DE, Border WA. Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis. Kidney Int 45: 916-927, 1994.